title: Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children.
abstract: The purpose of the present review is to summarise the current knowledge on the association between single nucleotide polymorphisms (SNPs) in the interferon L3 (IFNL3) gene and hepatitis C virus (HCV) infection in children. Many studies in adults have demonstrated that genetic variation in IFNL3 is a strong predictor of the virological response in treatment-naive patients with HCV genotype 1 who were treated with Pegylated-IFN-α and ribavirin. Genetic variation in IFNL3 is also associated with the spontaneous clearance of HCV. Thus far, few paediatric studies have explored the association between variations in the IFNL3 gene and either spontaneous or treatment-induced clearance of HCV. The CC genotype of the rs12979860 SNP is associated with the spontaneous clearance of HCV in children independently of HCV genotype. Four paediatric studies have shown that both the CC genotype of the rs12979860 SNP and the TT genotype of the rs8099917 SNP are associated with the treatment-induced (IFN monotherapy and Pegylated-IFN-α and ribavirin association) clearance of HCV, while the rs12980275 SNP did not affect the virological response. The possible role of IFNL3 gene variation as a pre-treatment and on-treatment predictor of virological response in children is highly attractive but still undetermined. Further paediatric studies are needed to evaluate if testing for SNPs in IFNL3, either alone or together with other predictors of response to treatment, could be used to direct treatment strategies, including an avoidance of unnecessary protease inhibitor therapy and the duration of treatment.
authors: Giuseppe Indolfi, Massimo Resti, Paediatric and Liver Unit, Meyer Children's University Hospital of Florence, I-50139 Florence, Italy.
authors: Giuseppe
authors: G
authors: Indolfi
authors: Giuseppe Indolfi, Massimo Resti, Paediatric and Liver Unit, Meyer Children's University Hospital of Florence, I-50139 Florence, Italy.
authors: Chiara
authors: C
authors: Azzari
authors: Giuseppe Indolfi, Massimo Resti, Paediatric and Liver Unit, Meyer Children's University Hospital of Florence, I-50139 Florence, Italy.
authors: Massimo
authors: M
authors: Resti
mesh_terms: D000328:Adult; D000367:Age Factors; D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000276:immunology / Q000472:pathogenicity; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics* / Q000276:immunology / Q000821:virology; D054884:Host-Pathogen Interactions; D006801:Humans; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D018579:Patient Selection; D010597:Pharmacogenetics; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D016896:Treatment Outcome; D019562:Viral Load; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D007372:Interferons; D007378:Interleukins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda
keywords: Children; Hepatitis C virus; IL28B; Interferon L3; Interferon-λ; Treatment; Virological response